Benzathine penicillin is formulated from two penicillin G molecules reacting with diphenylethylene diamine. It is active against Gram-positive bacteria including beta-hemolytic streptococci (groups A, B, C, G, H, L, and M) as well as Treponema pallidum and T. carateum. There has been no reported resistance to benzathine penicillin in Streptococcus pyogenes.
Benzathine penicillin is FDA-approved to treat the following:
1. Upper respiratory infection, group A streptococci
2. Pharyngitis, group A streptococci (Infectious Diseases Society of America [IDSA] guidelines)
3. Syphilis (CDC)
4. Yaws, bejel, and pinta
1. Upper respiratory infection, group A streptococci (e.g., pharyngitis)
2. Primary prevention of rheumatic fever
3. Secondary prevention of rheumatic fever
4. Pharyngitis, group A streptococci (IDSA)
5. Syphilis (off-label population) (CDC)
FDA Labeled Indications
Benzathine penicillin is in a class of beta-lactam antimicrobials. Beta-lactams are bactericidal antimicrobials. This type of antimicrobial inhibits the biosynthesis of the cell wall peptidoglycan during the stage of active multiplication. It inhibits bacterial peptidoglycan transpeptidase. This results in an osmotically unstable cell wall, leading to lysis of the cell wall, subsequent destruction of the bacterial cell, and death.
Benzathine penicillin is available as an injectable suspension that is administered intramuscularly, not intravenous, intra-arterial, or subcutaneous. The medication should be warmed to room temperature before administration to lessen the pain associated with the injection, and it should not be given near an artery or nerve. In adults, administer the injection to the upper outer quadrant of the buttocks. In children less than 2 years old, administer the injection to the mid-lateral muscle of the thigh, not the gluteal region, and rotate the injection site on repeat doses.
Benzathine penicillin is opaque and viscous with very low solubility. The antimicrobial is, therefore, slowly released from the site of injection and hydrolyzed to penicillin G. Due to the slow absorption and the hydrolysis, the concentration of the drug in the blood remain lower but for a prolonged period of time. After a 1.2 million unit injection, adults have detectable drug concentrations for 14 days, often longer.
The antimicrobial typically is manufactured in 600,000 units/1 mL, 1.2 million units/2 mL, or 2.4 million units/4 mL syringes. The antimicrobial is to be stored in a refrigerator from 36 to 46 degrees F (2 to 8 degrees C), never frozen. Dosing recommendations are as follows:
Infants and Children
The medication is excreted by renal tubular excretion.
There are no dose adjustments for patients with hepatic impairment.
Use with caution in patients with a seizure disorder, especially in patients with renal impairment, due to a potential increase in the risk of seizures.
Pregnancy (Category B)
Reproduction studies performed in mice, rats, and rabbits have revealed no evidence of harm to the fetus. Human experience with penicillin during pregnancy has not shown to have any adverse effects on the fetus. However, studies with women who are pregnant are inadequate or not well-controlled and cannot conclusively report harmful effects of penicillin medications on the fetus.
Soluble penicillin G is excreted in breast milk. Caution should be used.
Patients generally tolerate benzathine penicillin well, with pain from the injection being the most common concern. Other adverse events include hypersensitivity reactions. Patients with a previous history of hypersensitivity to penicillins or those with a history of asthma, hay fever, allergies, or urticaria, are at higher risk of hypersensitivity reactions. Hypersensitivity reactions can be serious and/or fatal and include the type-I, IgE-mediated reaction, also known as anaphylaxis. This type-I hypersensitivity reaction typically includes urticarial skin rash, itching, wheezing, dyspnea, nausea, vomiting, diarrhea, and can progress to hemodynamic instability and death. Any previous anaphylactic reaction or serious skin reaction (for example, Steven-Johnson or Toxic Epidermal Necrosis) to any penicillin is a contraindication for use. There have been previous reports that patients with anaphylactic or serious skin reactions from cephalosporins or carbapenems will have a type of cross-reactivity reaction that will also have such serious adverse events when administered any penicillin medication, but these reports are believed to be much lower than previously suspected.
The other adverse effect is known as a superinfection that can result from prolonged use. A superinfection can occur up to 2 months of post-antimicrobial treatment. These potentially fatal infections include C. difficile-associated diarrhea and pseudomembranous colitis.
Benzathine penicillin is contraindicated in patients who have had a previous anaphylactic reaction or serious skin reaction to any penicillin; for example, Steven-Johnson or toxic epidermal necrosis. There have been reports of patients with anaphylactic or serious skin reactions from cephalosporins or carbapenems having a type of cross-reactivity reaction that also results in serious adverse events when they are administered any penicillin antimicrobial, including benzathine penicillin, but these reports are believed to be much lower than previously suspected.
Observe for signs and symptoms of hypersensitivity reactions, including anaphylaxis, or superinfection.
Since a healthcare practitioner administers the medication by injection, overdoses are rare. An overdose has the potential to cause neuromuscular irritability or convulsive seizures.
Benzathine penicillin is often administered by healthcare team members including the nurse practitioner, primary care provider, internist, and infectious disease expert. While the drug is relatively safe it is important to observe the patient for an allergic reaction. Empirical use of this drug can lead to superinfections.
|||Walker GJ,Walker D,Molano Franco D,Grillo-Ardila CF, Antibiotic treatment for newborns with congenital syphilis. The Cochrane database of systematic reviews. 2019 Feb 15; [PubMed PMID: 30776081]|
|||Ndeikoundam Ngangro N,Viriot D,Fournet N,Pioche C,De Barbeyrac B,Goubard A,Dupin N,Berçot B,Fouéré S,Alcaraz I,Ohayon M,Spenatto N,Vernay-Vaisse C,Referents For The Regional Offices Of The French National Public Health Agency,Pillonel J,Lot F, Bacterial sexually transmitted infections in France: recent trends and patients' characteristics in 2016. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2019 Jan; [PubMed PMID: 30722812]|
|||Webber BJ,Kieffer JW,White BK,Hawksworth AW,Graf PCF,Yun HC, Chemoprophylaxis against group A streptococcus during military training. Preventive medicine. 2019 Jan; [PubMed PMID: 30393152]|
|||Struyve M,Meersseman W,Van Moerkercke W, Primary syphilitic proctitis : case report and literature review. Acta gastro-enterologica Belgica. 2018 Jul-Sep; [PubMed PMID: 30350534]|
|||Khan A,Sutcliffe N,Jawad AS, An old disease re-emerging: acute rheumatic fever. Clinical medicine (London, England). 2018 Oct; [PubMed PMID: 30287435]|
|||Benzathine Penicillin G 2006; [PubMed PMID: 30000197]|
|||Holland JV,Hardie K,de Dassel J,Ralph AP, Rheumatic Heart Disease Prophylaxis in Older Patients: A Register-Based Audit of Adherence to Guidelines. Open forum infectious diseases. 2018 Jun 1; [PubMed PMID: 29942824]|
|||Montagnat OD,Webster GR,Bulitta JB,Landersdorfer C,Wyber R,Sheel M,Carapetis JR,Boyd BJ, Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD). Drug delivery and translational research. 2018 Jun; [PubMed PMID: 29404981]|